K Pharma,Inc. Logo

K Pharma,Inc.

Develops iPS cell-based drugs and regenerative medicine for central nervous system disorders.

4896 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
港区六本木七丁目7番7号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

K Pharma, Inc. is a biotechnology company established as a spin-off from the Keio University School of Medicine to commercialize research in induced pluripotent stem (iPS) cell technology. The company engages in the research, development, manufacturing, and sale of pharmaceuticals and regenerative medicine products. Its business is centered on two key areas: iPS drug discovery, which utilizes disease-specific iPS cells to develop new therapies, and regenerative medicine. The company's primary therapeutic focus is on the central nervous system (CNS), developing applications for nerve regeneration to treat conditions such as spinal cord injuries and cerebral infarctions.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for K Pharma,Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-14 02:30
Interim Report
半期報告書-第9期(2025/01/01-2025/12/31)
Japanese 179.3 KB
2025-08-14 02:30
Regulatory News Service
確認書
Japanese 8.8 KB
2025-03-28 02:01
Regulatory News Service
臨時報告書
Japanese 24.2 KB
2025-03-28 02:00
Regulatory News Service
内部統制報告書-第8期(2024/01/01-2024/12/31)
Japanese 22.4 KB
2025-03-28 02:00
Annual Report
有価証券報告書-第8期(2024/01/01-2024/12/31)
Japanese 1.5 MB
2025-03-28 02:00
Regulatory News Service
確認書
Japanese 8.8 KB
2024-08-14 08:00
Regulatory News Service
確認書
Japanese 8.9 KB
2024-08-14 08:00
Interim Report
半期報告書-第8期(2024/01/01-2024/12/31)
Japanese 182.0 KB
2024-05-14 02:00
Quarterly Report
四半期報告書-第8期第1四半期(2024/01/01-2024/03/31)
Japanese 136.5 KB
2024-05-14 02:00
Regulatory News Service
確認書
Japanese 8.8 KB
2024-03-29 02:30
Regulatory News Service
臨時報告書
Japanese 22.6 KB
2024-03-28 07:01
Regulatory News Service
確認書
Japanese 8.8 KB
2024-03-28 07:00
Regulatory News Service
内部統制報告書-第7期(2023/01/01-2023/12/31)
Japanese 22.4 KB
2024-03-28 07:00
Annual Report
有価証券報告書-第7期(2023/01/01-2023/12/31)
Japanese 1.5 MB
2023-11-13 07:01
Regulatory News Service
確認書
Japanese 8.8 KB

Automate Your Workflow. Get a real-time feed of all K Pharma,Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for K Pharma,Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
GNI  Group Ltd. Logo
Biopharma firm developing novel drugs for cancer and inflammatory diseases using genetics.
Japan 2160
Goodwill Pharma Plc Logo
Integrated pharma CDMO developing Rx/OTC meds, supplements & devices for CEE markets.
Hungary GWPH
Grifols S.A. Logo
Leading producer of plasma-derived medicines for patients with rare and chronic diseases.
Spain GRF
Grindeks Logo
Develops & manufactures pharmaceuticals for cardiovascular, CNS, cancer, and diabetes globally.
Latvia GRD1R
Guard Therapeutics International AB Logo
Clinical-stage biotech developing drugs to prevent acute kidney injury during open-heart surgery.
Sweden GUARD
Haleon PLC Logo
A global consumer healthcare leader providing trusted, science-backed OTC brands for everyday health.
United Kingdom HLN
Halychpharm Logo
A pharmaceutical manufacturer of finished medicines and plant-derived phytochemical substances.
Ukraine GFARM
Hansa Biopharma Logo
Develops antibody-cleaving enzymes to treat rare diseases and enable organ transplants.
Sweden HNSA
HEALIOS K.K. Logo
Develops iPS and somatic stem cell therapies for diseases like ARDS and cancer.
Japan 4593
Heartseed株式会社 Logo
Develops iPSC-derived cell therapies to regenerate heart tissue for heart failure.
Japan 219A

Talk to a Data Expert

Have a question? We'll get back to you promptly.